INTRODUCTION
CISPLATIN has been shown to have some activity in gastric cancer but its application is limited because of toxicity [ 11. In recent years, the search for platinum compounds with reduced toxicity has been the main goal in the development of platinum analogs. logical toxicity. Among nine pretreaed patients receiving a median iproplatin dose of 180 mg/m* (range 16Q-200), the median WEC and platelet nadir after the first cycle were 4.7 X 103/p.1 (range 2.4-11.4 X 103/pJ) and 185 X 103/~1 (range 132-300 X 103/p.1). Among 14 non-pretreated patients receiving a median iproplatin dose of 240 mg/m* (range 180-270) the median WEC and platelet nadir after the first cycle were 5.3 x 103/$ (range 3.4-10.4 X 103/~1) and 127 X 103/$ (range 55-240). At the second cycle the dose had to be reduced in one pretreated patient but could be increased in 11 (three pretreated, eight untreated). Nausea and vomiting were almost universal (grade 2 and 3: 46 and 30%); diarrhea occurred in 35% (grade 2 and 3: 15 and 4%).
DISCUSSION
The results of this study indicate limited antitumor activity of iproplatin in gastric cancer (95% confidence intervals in the untreated group: O-30%; in the pretreated group: 2-55%). This minimal response rate is comparable to that observed with carboplatin
[5]. The lack of significant thrombocytopenia and the low incidence of the other dose-limiting toxicity, diarrhea, suggest that in the current study the initial dosage of iproplatin could have been substantially increased. In view of the low response rate achieved with the recommended dose of 270 mg/m* in previously untreated patients, it is unlikely, however, that higher doses could have resulted in better antitumor activity.
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